CL 329998

Drug Profile

CL 329998

Alternative Names: DMG-MINO

Latest Information Update: 13 Jan 2002

Price : $50

At a glance

  • Originator Wyeth
  • Class Antibacterials; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 13 Jan 2002 Discontinued-Preclinical for Bacterial infections in USA (Unknown route)
  • 06 Sep 1996 An in vitro study has been added to the antimicrobial activity section
  • 20 Jun 1996 An in vitro study on the efficacy of CL 329998 against mycobacteria has been added to the antimycobacterial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top